Literature DB >> 1905067

Thromboembolism and bleeding tendency in congenital factor XII deficiency--a study on 74 subjects from 14 Swiss families.

B Lämmle1, W A Wuillemin, I Huber, M Krauskopf, C Zürcher, R Pflugshaupt, M Furlan.   

Abstract

In order to assess the clinical implications of hereditary F XII deficiency, all available members of Swiss families with F XII deficiency were investigated. Based on the F XII:C values and the family pedigree, the 74 subjects, aged 8-82 years, were classified as homozygotes/double heterozygotes for F XII deficiency (n = 18), as obligatory (n = 20) or possibly (n = 25) heterozygotes, respectively, and as normals (n = 11). None of the 18 subjects with F XII:C less than 0.01 U/ml and only one possibly heterozygous woman had an abnormal bleeding tendency, confirming the notion that Hageman trait generally does not result in a hemorrhagic diathesis. Two of the 18 subjects with severe F XII deficiency had suffered from venous thromboembolic disease at age less than 40 years. One heterozygous woman had a leg ulcer probably due to venous thrombosis. Thus, whereas homozygous F XII deficiency may be associated with an increased risk for venous thromboembolic disease, partial F XII deficiency is not, by itself, a strong risk factor for thrombosis. Whereas 17 of the 18 subjects with F XII:C less than 0.01 U/ml had no detectable F XII:Ag, one cross reacting material-positive F XII deficient subject (F XII:Ag = 0.11 U/ml) was identified. The dysfunctional F XII, present in this subject's plasma and tentatively called F XII Bern, is the fourth abnormal F XII molecule identified so far.

Entities:  

Mesh:

Year:  1991        PMID: 1905067

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  33 in total

Review 1.  [Coagulation management in patients with liver disease].

Authors:  A Bienholz; A Canbay; F H Saner
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-05-05       Impact factor: 0.840

Review 2.  Pregnancies and oral contraceptive therapy in severe (homozygons) FXII deficiency: a study in 12 patients and review of the literature.

Authors:  A Girolami; N Zocca; B Girolami; A M Lombardi; F Fabris
Journal:  J Thromb Thrombolysis       Date:  2004-12       Impact factor: 2.300

3.  Sequence variation and genetic evolution at the human F12 locus: mapping quantitative trait nucleotides that influence FXII plasma levels.

Authors:  Francesc Calafell; Laura Almasy; Maria Sabater-Lleal; Alfonso Buil; Carolina Mordillo; Anna Ramírez-Soriano; Martin Sikora; Juan Carlos Souto; John Blangero; Jordi Fontcuberta; José Manuel Soria
Journal:  Hum Mol Genet       Date:  2009-11-23       Impact factor: 6.150

4.  Comparative incidence of thrombosis in reported cases of deficiencies of factors of the contact phase of blood coagulation.

Authors:  A Girolami; N Candeo; G Berti De Marinis; E Bonamigo; B Girolami
Journal:  J Thromb Thrombolysis       Date:  2011-01       Impact factor: 2.300

5.  Structures of human plasma β-factor XIIa cocrystallized with potent inhibitors.

Authors:  Alexey Dementiev; Abel Silva; Calvin Yee; Zhe Li; Michael T Flavin; Hing Sham; James R Partridge
Journal:  Blood Adv       Date:  2018-03-13

6.  Thrombotic events in severe FXII deficiency in comparison with unaffected family members during a long observation period.

Authors:  Antonio Girolami; Silvia Ferrari; Elisabetta Cosi; Bruno Girolami; Maria Luigia Randi
Journal:  J Thromb Thrombolysis       Date:  2019-04       Impact factor: 2.300

Review 7.  In vivo roles of factor XII.

Authors:  Thomas Renné; Alvin H Schmaier; Katrin F Nickel; Margareta Blombäck; Coen Maas
Journal:  Blood       Date:  2012-09-19       Impact factor: 22.113

8.  Symptomatic combined homozygous factor XII deficiency and heterozygous factor V Leiden. luscaber@tin.it.

Authors:  A Girolami; P Simioni; L Scarano; B Girolami; P Zerbinati
Journal:  J Thromb Thrombolysis       Date:  2000-04       Impact factor: 2.300

9.  Novel family of insect salivary inhibitors blocks contact pathway activation by binding to polyphosphate, heparin, and dextran sulfate.

Authors:  Patricia H Alvarenga; Xueqing Xu; Fabiano Oliveira; Andrezza C Chagas; Clarissa R Nascimento; Ivo M B Francischetti; Maria A Juliano; Luiz Juliano; Julio Scharfstein; Jesus G Valenzuela; José M C Ribeiro; John F Andersen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-10-03       Impact factor: 8.311

Review 10.  C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2.

Authors:  C E Hack; A C Ogilvie; B Eisele; A J Eerenberg; J Wagstaff; L G Thijs
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.